A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria
Status:
Unknown status
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
A double blind, randomized, cross over study in type 1 diabetic patients. 20 patients, age
18-65 years is treated with spironolacton (Hexalacton (R)) for 60 days followed by 60 days
treatment with placebo(or opposite). Primary aim: albuminuria, an expected decrease during
hexalacton treatment. Secondary aim: ambulatory blood pressure, GFR, plasma-renin,
angiotensin, aldosteron.
Phase:
Phase 4
Details
Lead Sponsor:
Steno Diabetes Center Steno Diabetes Center Copenhagen